Add like
Add dislike
Add to saved papers

The impacts of metabolic syndrome and lifestyle on the prevalence of benign prostatic hyperplasia requiring treatment: historical cohort study of 130 454 men.

BJU International 2019 January
OBJECTIVE: To investigate the influences of lifestyle and metabolic syndrome (MetS) on the prevalence of benign prostatic hyperplasia (BPH) requiring treatment using a large historical cohort.

PATIENTS AND METHODS: This study included 130 454 men selected from the National Health Information Database of the National Health Insurance Service in South Korea. Men were divided into the two groups according to the presence of MetS. A generalised estimating equation was used to assess the predictors of BPH requiring treatment after adjusting for other variables.

RESULTS: The prevalence of BPH requiring treatment was significantly higher in men with MetS, except in men aged <50 years. Multivariable analysis showed that MetS was associated with higher prevalence of BPH requiring treatment regardless of age, and that a low income was associated with a lower prevalence in men aged ≥60 years. Alcohol consumption was negatively associated with the prevalence of BPH requiring treatment in all age groups, except in men aged <50 years. Amongst the MetS components, low high-density lipoprotein cholesterol (HDL-C) levels showed the strongest association with the prevalence of BPH requiring treatment in all age categories, although all MetS components were correlated with an increased prevalence of BPH requiring treatment, particularly in men aged ≥50 years.

CONCLUSION: MetS and its components, particularly low HDL-C levels, were strongly correlated with an increased prevalence of BPH requiring treatment. In addition, moderate alcohol intake and elderly men from lower socioeconomic strata were associated with a decreased prevalence of BPH requiring treatment in our cohort.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app